Drug-related problems in hospitalized oncology patients, with special focus on radiotherapy units: Implications for oncology pharmacy practice [0.03%]
住院肿瘤患者的药物相关问题，尤其是放射治疗单位的药物相关问题及其对肿瘤临床药师实践的影响
Katarzyna Regulska,Marcin Michalak,Beata Janiszewska et al.
Katarzyna Regulska et al.
IntroductionDrug-related problems (DRPs) represent a major challenge in contemporary oncology. In healthcare systems with limited clinical pharmacy resources, identification of high-risk patient groups and treatment settings is - from a cli...
Exploring an enhanced role of the pharmacy technician in cancer services within the uk independent sector [0.03%]
探索英国私营部门药房技术员在癌症服务中的增强作用
Jared Bannister,Philip Jones,Netty Annette Cracknell
Jared Bannister
IntroductionCancer services within the independent sector often operate with limited oncology pharmacists on site. This causes operational issues when leave occurs and can also limit overall capacity. While locum cover is a potential option...
Incidence of endocrine toxicities in patients with solid tumor malignancies receiving curative-intent immune checkpoint inhibitor (ICI) therapy: A single institution experience [0.03%]
单中心大样本回顾性分析免疫检查点抑制剂根治性治疗实体瘤患者的内分泌毒性发生率
Hana Kurz,Hang Zeng,Miranda Benfield et al.
Hana Kurz et al.
IntroductionImmune checkpoint inhibitors (ICIs) are used across many solid tumor malignancies. The mechanism varies depending on the agent but ultimately leads to immune system activation by targeting key regulators of immune tolerance. Tox...
Evaluation of real-world hazardous drug wipe test data to assess surface contamination following the use of a closed system transfer device [0.03%]
评估真实世界危险药物擦拭试验数据以评估封闭系统传输设备使用后的表面污染情况
Akshar N Patel,Marie-Claude Gutekunst,Christopher R Curtin et al.
Akshar N Patel et al.
Introduction/Rationale for Study: This retrospective, observational analysis evaluated real-world hazardous drug (HD) surface wipe test data collected from U.S. healthcare facilities following implementation of a closed-system transfer devi...
Immortal time bias in contemporary CDK4/6 inhibitor studies: Evidence from target trial emulation [0.03%]
当代CDK4/6抑制剂研究中的永生时间偏倚：来自靶标试验仿真的证据
G Hari Prakash,Sunil Kumar,Kiran Pk et al.
G Hari Prakash et al.
BackgroundObservational studies increasingly inform treatment decisions for CDK4/6 inhibitors in metastatic breast cancer, yet their validity is compromised by immortal time bias, a mechanistic bias that inflates treatment benefits when fol...
Development of a structured oncology pharmacy medication resource to support patient counselling in outpatient cancer care: A cross-sectional evaluation [0.03%]
用于门诊癌症护理中支持患者咨询的结构化肿瘤药学资源开发：横断面评价
Seham El Deeb,Ismail Bennani,Ali Cherif Chefchaouni et al.
Seham El Deeb et al.
BackgroundOutpatient oncology pharmacies manage increasingly complex antineoplastic, hormonal, and supportive therapies that require precise and consistent patient counselling to ensure safe and effective use. Oral anticancer agents, hormon...
Fungal prophylaxis and prevalence of fungal infections in children with cancer [0.03%]
儿童癌症患者的抗真菌预防与真菌感染的流行率关系研究
Jessica Loucks,Valeria Carvalho Morrison,Roxane Carr et al.
Jessica Loucks et al.
PurposeChildren with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and allogeneic haemopoietic stem cell transplantation (HSCT) are at high risk of invasive fungal infection (IFI), which contributes to morbidity and mort...
Impact of the oncoral patient education follow-up program on the acquisition of knowledge about oral anticancer drugs [0.03%]
安珂教育随访项目对口服抗肿瘤药物认知的影响研究
Virginie Larbre,Nicolas Romain Scelle,Chloé Herledan et al.
Virginie Larbre et al.
BackgroundMultidisciplinary care programs are developed to secure oral anticancer treatments and ensure continuity of care. The aim of this study is to assess the impact of this educational pathway on patients' knowledge of oral anticancer ...
Toxic epidermal necrolysis during chemo-immunotherapy treatment with pembrolizumab [0.03%]
化疗免疫治疗期间帕博利珠单抗引起中毒性表皮坏死松解症
Araceli Iglesias-Santamaría,Nerea Rodríguez González
Araceli Iglesias-Santamaría
IntroductionImmune checkpoint inhibitors (ICIs), such as anti-PD-1/PD-L1 antibodies, improve survival in patients with advanced malignancies. However, their combination with chemotherapy may increase the incidence of severe immune-related a...
Safe use of ribociclib in a patient with HR+/HER2- metastatic breast cancer receiving chronic hemodialysis [0.03%]
肾透析HR阳性/HER2阴性转移性乳腺癌患者中利伯西林的安全使用
Dilek Çağlayan,Melek Çağlayan
Dilek Çağlayan
İntroductionThe standard treatment for hormone receptor-positive and HER2-negative metastatic breast cancer is a combination of CDK4/6 inhibitors and endocrine therapy.Case reportIn this case, our aim was to demonstrate the safety and effe...